Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine.

Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M, Sinangil F, D'Souza P, Rodriguez-Chavez IR, DeCamp A, Giganti M, Berman PW, Self SG, Montefiori DC.

J Infect Dis. 2010 Aug 15;202(4):595-605. doi: 10.1086/654816.

2.

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.

Parren PW, Gauduin MC, Koup RA, Poignard P, Fisicaro P, Burton DR, Sattentau QJ.

Immunol Lett. 1997 Jun 1;57(1-3):105-12. Review. Corrected and republished in: Immunol Lett. 1997 Jul;58(2):125-32.

PMID:
9232434
3.

Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".

Parren PW, Gauduin MC, Koup RA, Poignard P, Sattentau QJ, Fisicaro P, Burton DR.

Immunol Lett. 1997 Jul;58(2):125-32. Review.

PMID:
9271324
4.

The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.

O'Connell RJ, Kim JH, Excler JL.

Expert Rev Vaccines. 2014 Dec;13(12):1489-500. doi: 10.1586/14760584.2014.951335. Epub 2014 Aug 28. Review.

PMID:
25163695
5.

Induction of immunity to human immunodeficiency virus type-1 by vaccination.

McElrath MJ, Haynes BF.

Immunity. 2010 Oct 29;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011. Review.

6.

HIV-1 vaccines: challenges and new perspectives.

Excler JL, Robb ML, Kim JH.

Hum Vaccin Immunother. 2014;10(6):1734-46. doi: 10.4161/hv.28462. Epub 2014 Mar 17. Review.

7.

Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.

Georgiev IS, Gordon Joyce M, Zhou T, Kwong PD.

Curr Opin HIV AIDS. 2013 Sep;8(5):382-92. doi: 10.1097/COH.0b013e328363a90e. Review.

8.

Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).

Vaine M, Lu S, Wang S.

BioDrugs. 2009;23(3):137-53. doi: 10.2165/00063030-200923030-00001. Review.

9.

Development of prophylactic vaccines against HIV-1.

Schiffner T, Sattentau QJ, Dorrell L.

Retrovirology. 2013 Jul 17;10:72. doi: 10.1186/1742-4690-10-72. Review.

10.

Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.

Kim JH, Excler JL, Michael NL.

Annu Rev Med. 2015;66:423-37. doi: 10.1146/annurev-med-052912-123749. Epub 2014 Oct 17. Review.

PMID:
25341006
11.

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.

Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyƶ EM, Montefiori DC, McCutchan FE, Michael NL.

Virology. 2008 Jun 5;375(2):315-20. doi: 10.1016/j.virol.2008.02.007. Epub 2008 Mar 25. Review.

12.

Receptor binding domain based HIV vaccines.

Liu H, Bi W, Wang Q, Lu L, Jiang S.

Biomed Res Int. 2015;2015:594109. doi: 10.1155/2015/594109. Epub 2015 Jan 15. Review.

Items per page

Supplemental Content

Write to the Help Desk